Ertapenem peritoneal fluid concentrations in adult surgical patients

被引:8
作者
Arrigucci, Silvia [1 ]
Garcea, Alessandro [2 ]
Fallani, Stefania [1 ]
Cassetta, Maria Iris [1 ]
Canonico, Giuseppe [2 ]
Tonelli, Francesco [2 ]
Mazzei, Teresita [1 ]
Novelli, Andrea [1 ]
机构
[1] Univ Florence, Dept Pharmacol, I-50139 Florence, Italy
[2] Univ Florence, Dept Clin Physiopathol, Surg Unit, I-50134 Florence, Italy
关键词
Ertapenem; Peritoneal fluid; Intra-abdominal infections; Pharmacokinetics; PHARMACOKINETICS; PENETRATION; CEFOTETAN;
D O I
10.1016/j.ijantimicag.2008.09.015
中图分类号
R51 [传染病];
学科分类号
100201 [内科学];
摘要
Ertapenem, a novel carbapenem, is approved for the treatment of mild to severe intra-abdominal infections (IAIs), although its in vivo concentrations in peritoneal fluid are unknown. The purpose of this study was to determine the peritoneal fluid concentration of ertapenem after a single 1 g intravenous dose. After informed consent, 21 patients (9 females and 12 males; mean +/- standard deviation (S. D.) age 50.2 +/- 17.7 years) requiring intra-abdominal surgery were enrolled. Plasma and peritoneal fluid samples were taken at fixed times during surgery. Drug concentrations were determined by high-performance liquid chromatography (HPLC) with ultraviolet detection. Mean +/- S. D. ertapenem peritoneal fluid concentrations were 64.3 +/- 23.4 mg/L at 1h and 31.3 +/- 26.5 mg/L at 3 h after administration. The mean tissue/plasma ratio ranged from 46.7% to 83.1%. The mean peritoneal fluid concentrations were well above the MIC(90) (minimum inhibitory concentration for 90% of the organisms) for susceptible bacteria found in IAIs, especially Escherichia coli, viridans streptococci, Enterobacteriaceae, Klebsiella spp. and Bacteroides fragilis, during the entire sampling time. These pharmacokinetic results support the assumption that ertapenem might be suitable for the treatment of IAIs. (c) 2008 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:371 / 373
页数:3
相关论文
共 15 条
[1]
Baquero F, 2006, Rev Esp Quimioter, V19, P51
[2]
Pharmacodynamic principles of antimicrobial therapy in the prevention of resistance [J].
Burgess, DS .
CHEST, 1999, 115 (03) :19S-23S
[3]
Intraoperative positive fluid balance improves tissue diffusion of ceftizoxime [J].
Di Filippo, A ;
Cammelli, R ;
Novelli, A ;
Mazzei, T ;
Tonelli, F ;
Fallani, S ;
Cassetta, MI ;
Messeri, D ;
De Gaudio, AR .
CHEMOTHERAPY, 2005, 51 (2-3) :51-56
[4]
In vitro activity of ertapenem against common clinical isolates in relation to human pharmacokinetics [J].
Friedland, I ;
Mixson, LA ;
Majumdar, A ;
Motyl, M ;
Woods, GL .
JOURNAL OF CHEMOTHERAPY, 2002, 14 (05) :483-491
[5]
Determination of free ertapenem in plasma and bronchoalveolar lavage by high-performance liquid chromatography with ultraviolet detection [J].
Gordien, JB ;
Boselli, E ;
Fleureau, C ;
Allaouchiche, B ;
Janvier, G ;
Lalaude, O ;
Saux, MC ;
Breilh, D .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2006, 830 (02) :218-223
[6]
LINDER MM, 1987, CHIRURG, V58, P84
[7]
Properties and potential of ertapenem [J].
Livermore, DM ;
Sefton, AM ;
Scott, GM .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 52 (03) :331-344
[8]
Pharmacokinetics of ertapenem in healthy young volunteers [J].
Majumdar, AK ;
Musson, DG ;
Birk, KL ;
Kitchen, CJ ;
Holland, S ;
McCrea, J ;
Mistry, G ;
Hesney, M ;
Xi, L ;
Li, SX ;
Haesen, R ;
Blum, RA ;
Lins, RL ;
Greenberg, H ;
Waldman, S ;
Deutsch, P ;
Rogers, JD .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (11) :3506-3511
[9]
PENETRATION OF CEFOTETAN INTO SUCTION SKIN BLISTER FLUID AND TISSUE-HOMOGENATES IN PATIENTS UNDERGOING ABDOMINAL-SURGERY [J].
MAZZEI, T ;
TONELLI, F ;
NOVELLI, A ;
FICARI, F ;
MAZZONI, C ;
ANASTASI, A ;
PERITI, P .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (09) :2221-2223
[10]
TISSUE DISTRIBUTION OF CEFOTETAN IN PATIENTS WITH CROHNS-DISEASE [J].
MAZZEI, T ;
TONELLI, F ;
ANASTASI, A ;
FICARI, F ;
NOVELLI, A ;
PERITI, P .
CHEMOTHERAPY, 1991, 37 (05) :297-302